Phaseline

Targets › BRAF

BRAF (Serine/threonine-protein kinase B-raf): drug programs, companies and trials

26 programs from 18 companies in 126 trials: 79 Phase 2, 31 Phase 1, 12 Phase 3, 4 Phase 4; Oncology, Hematology, Gastroenterology; next expected readout Nov 2026.

Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway. (UniProt, P15056)

Open in Phaseline: the race on BRAF, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisDabrafenib
Serine/threonine-protein kinase B-raf inhibitor
BRAFPhase 4Diffuse Astrocytoma; Melanoma; Differentiated Thyroid Cancer (DTC); Advanced Thyroid Cancer Patients Who Received Target Therapy …Nov 2026
PfizerEncorafenib
Serine/threonine-protein kinase B-raf inhibitor
BRAFPhase 4Solid Tumors; Melanoma; Neoplasms; Metastatic Colorectal Cancer …Jan 2027
Pierre Fabre MedicamentEncorafenib
Serine/threonine-protein kinase B-raf inhibitor
BRAFPhase 3Melanoma; Non-Small Cell Lung CancerDec 2026
ErascaNaporafenib
B-raf/RAF proto-oncogene serine/threonine-protein kinase inhibitor
RAF1, BRAFPhase 3Advanced or Metastatic NRAS-mutant Melanoma; Advanced or Metastatic Solid TumorsDec 2026
National Cancer Institute (NCI)Dabrafenib Mesylate
Serine/threonine-protein kinase B-raf inhibitor
BRAFPhase 3Clinical Stage III Cutaneous Melanoma AJCC v8; Advanced Lymphoma; Stage III Cutaneous Melanoma AJCC v7; Anaplastic Astrocytoma …Dec 2026
Shanghai Kechow PharmaVemurafenib
Serine/threonine-protein kinase B-raf inhibitor
BRAFPhase 3Colorectal Cancer MetastaticDec 2026
Day One BiopharmaceuticalsTovorafenib
RAF serine/threonine protein kinase inhibitor
RAF1, BRAF, ARAFPhase 3Low-grade Glioma; Craniopharyngioma, Child; Recurrent Langerhans Cell Histiocytosis; Hairy Cell LeukemiaMay 2027
RocheSorafenib
Serine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor
RAF1, PDGFRB, KIT, FLT3, BRAFPhase 3Unresectable Hepatocellular Carcinoma; AML (Acute Myeloid Leukemia); Locally Advanced Thyroid Gland Carcinoma; Hepatocellular Carcinoma …–
RocheVemurafenib
Serine/threonine-protein kinase B-raf inhibitor
BRAFPhase 2Non-small Cell Lung Cancer; Thyroid Gland Follicular Carcinoma; Colorectal Carcinoma; Hairy Cell Leukemia …Nov 2026
Nanfang Hospital, Southern Medical UniversityDonafenib
multi-targeted tyrosine kinase inhibitor
BRAF, FLT3, RETPhase 2Unresectable Hepatocellular CarcinomaDec 2026
Fudan UniversityVermofenib
BRAF V600E inhibitor
BRAFPhase 2Colorectal Cancer MetastaticDec 2026
NovartisNaporafenib (LXH254)
B-raf/RAF proto-oncogene serine/threonine-protein kinase inhibitor
RAF1, BRAFPhase 2Melanoma; EGFR-mutant Non-small Cell Lung CancerFeb 2027
National Cancer Institute (NCI)Sorafenib Tosylate
Serine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor
RAF1, PDGFRB, KIT, FLT3, BRAFPhase 2Gastrointestinal Stromal Tumor; Acute Myeloid Leukemia; Advanced Malignant Solid NeoplasmMar 2027
Shanghai Changzheng HospitalChidamide
RAF inhibitor
BRAFPhase 2Advanced Colorectal Cancer in the Third-line Treatment and BeyondApr 2027
Fore Biotherapeuticsplixorafenib
Serine/threonine-protein kinase B-raf inhibitor
BRAFPhase 2Cancer Harboring BRAF AlterationsDec 2027
Hanmi Pharmaceutical CompanyBelvarafenib
RAF serine/threonine protein kinase inhibitor
RAF1, BRAF, ARAFPhase 2Advanced or Metastatic MelanomaSep 2029
Ruijin HospitalGiritinib
RAF inhibitor
BRAFPhase 2AMLMar 2030
Yu WangDonafenib
Multikinase inhibitor targeting BRAF, VEGFR, and FLT3
BRAF, VEGFR, FLT3Phase 2Thyroid Cancer–
RocheBelvarafenib
RAF serine/threonine protein kinase inhibitor
RAF1, BRAF, ARAFPhase 1Melanoma; Primary Brain TumorDec 2026
Haisco Pharmaceutical GroupHSK42360
BRAF V600 inhibitor
BRAFPhase 1Solid Tumors; Malignant Brain TumorsJul 2027
PfizerPF-07799544
BRAF inhibitor
BRAFPhase 1MelanomaAug 2027
PfizerPF-07799933
BRAF inhibitor
BRAFPhase 1MelanomaAug 2027
Institut de Recherches Internationales ServierS241656
RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III)
BRAF, CRAF, KRAS, NRASPhase 1Non-small Cell Lung CancerJun 2028
Pierre Fabre MedicamentKIN-2787
BRAF inhibitor
BRAFPhase 1Solid Tumor, AdultNov 2028
Haisco Pharmaceutical GroupHSK42360-Na
BRAF V600 inhibitor
BRAFPhase 1Solid Tumors (Phase 1); Metastatic Colorectal Cancer (CRC)Dec 2028
IpsenTovorafenib
RAF serine/threonine protein kinase inhibitor
RAF1, BRAF, ARAFPhase 1Low-grade GliomaJul 2030

Conditions

Melanoma (12) Thyroid Cancer (4) Hairy Cell Leukemia (4) Hepatocellular Carcinoma (4) Neoplasms (3) Solid Tumors (3) Colorectal Cancer (3) Low-grade Glioma (3) Advanced Colorectal Cancer in the Third-line Treatment and Beyond (3) Metastatic Malignant Neoplasm in the Brain (2) Haematological Malignancy (2) Colorectal Cancer Metastatic (2)

Modalities

small molecule (15), mixed (6), antibody (4), protein or peptide (1)

Companies

Roche (3) Pfizer (3) Pierre Fabre Medicament (2) Novartis (2) Haisco Pharmaceutical Group (2) National Cancer Institute (NCI) (2) Erasca (1) Fore Biotherapeutics (1) Fudan University (1) Ruijin Hospital (1) Yu Wang (1) Shanghai Kechow Pharma (1) Day One Biopharmaceuticals (1) Nanfang Hospital, Southern Medical University (1) Ipsen (1) Institut de Recherches Internationales Servier (1) Hanmi Pharmaceutical Company (1) Shanghai Changzheng Hospital (1)

Related targets

RAF1 (8) FLT3 (4) ARAF (4) PDGFRB (2) KIT (2) VEGFR (1) RET (1) CRAF (1) KRAS (1) NRAS (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.